Particular attention was paid to the risk of bladder cancer, because previous meta-analyses suggested there was an increased risk of this cancer during treatment with SGLT-2 inhibitors, in particular with empagliflozin [5]. The gene discussed is SLC5A2; the disease is urinary bladder carcinoma.